A0805 Vascular Aging and Preclinical Target Organ Damage in Community-Dwelling Elderly

Abstract

Objectives: Vascular aging represents a mediating step between risk factors and cardiovascular (CV) events. And preclinical target organ damage (TOD) integrates the cumulative effects of CV risk factors. This study is focusing on the relationships between healthy vascular aging (HVA) and preclinical TOD. Methods: Cross-sectional data from the Northern Shanghai Study (NSS, Clinicaltrials.gov NCT02368938), prospectively recruited from June 2014 to June 2017 [n = 2098, 45.52% men, aged 71.3 ± 6.1 years]. Preclinical TODs were assessed in all the participants. Other clinical information was obtained by standard questionaire. HVA was defined as absence of hypertension and a relatively normal cf-PWV (presented per age decade and blood pressure category). We fitted logistic regression models to assess the probability of Non-HVA in association with all the preclinical TOD. Results: In this analysis, 642 (30.6%) elderly participants had HVA, the prevalence of HVA decreased from 30.84% (aged 65–66) to 20.72% (aged ≥ 75). In multivariate regression models, after adjusting confounders, increased age, increased SBP, increased fasting glucose, increased BMI and family history of premature cardiovascular disease (CVD) were significantly associated with Non-HVA (p = 0.005 to p < 0.001). And after adjustments, Non-HVA status was associated with left ventricular diastolic dysfunction (LVDD) (OR, 1.525 (1.171, 1.988), p = 0.003), left ventricular hypertrophy (LVH) (OR, 1.858 (1.228, 2.811), p = 0.002) and micro-albuminuria (MAU) (OR, 1.525 (1.171, 1.988), p = 0.002). Conclusion: Management of blood pressure and metabolic profile may help to prevent or delay vascular aging. And accelerated vascular aging is associated with LVH, LVDD and MAU, which provide a potential vascular target to reverse or terminate cardiac and renal TOD.